Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of SGM-101 fluorescence-guided surgery in colorectal cancer
NL-OMON54662Phase 3Completed
- Sponsor
- SurgiMab
- Start
- May 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of sgm-101 in colorectal cancer (CRC) (2 arms), sponsored by SurgiMab. Primary endpoint: Primary efficacy endpoint P1. Started May 2019; status: completed.
02
Drugs
sgm-101
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON54662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54662.